Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, May 9, 2024, to review the company's first quarter 2024 financial results and provide business updates.
马萨诸塞州剑桥，2024年5月2日（GLOBE NEWSWIRE）——专注于释放RNA药物改变人类健康的广泛潜力的临床阶段生物技术公司Wave Life Sciences Ltd.（纳斯达克股票代码：WVE）将于美国东部时间2024年5月9日星期四上午8点30分举办网络直播和电话会议，审查该公司2024年第一季度的财务业绩并提供业务最新情况。
The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events.
网络直播和电话会议可访问Wave Life Sciences网站投资者专区的 “投资者活动”：ir.wavelifesciences.com/events-publications/events-publications/events-publications/events。
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: available here. Once registered, participants will receive the dial-in information.
计划参与实时电话问答部分的分析师可以通过以下音频会议链接加入电话会议：可在此处获得。注册后，参与者将收到拨入信息。
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
直播结束后，网络直播的存档版本将在Wave Life Sciences网站上公布。
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington's disease, as well as a preclinical program in obesity. Driven by the calling to "Reimagine Possible", Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit and follow Wave on X (formerly Twitter) and LinkedIn.
关于 Wave 生命科学
Wave Life Sciences（纳斯达克股票代码：WVE）是一家生物技术公司，致力于释放RNA药物改变人类健康的广泛潜力。Wave 的 RNA 药物平台 PRISMTM，结合了多种模式、化学创新和对人类遗传学的深刻见解，实现了治疗罕见和流行疾病的科学突破。其RNA靶向模式工具包包括编辑、剪接、RNA干扰和反义沉默，为Wave设计和可持续交付最适合疾病生物学的候选药物提供了无与伦比的能力。Wave的多元化项目包括杜兴氏肌肉萎缩症、Alpha-1抗胰蛋白酶缺乏症和亨廷顿氏病的临床项目，以及肥胖症的临床前项目。在 “重新构想可能” 的号召下，Wave正在引领人们走向一个人类潜能不再受到疾病负担阻碍的世界。Wave 总部位于马萨诸塞州剑桥。有关Wave的科学、管道和人员的更多信息，请在X（前身为推特）和领英上访问并关注Wave。
Investor Contact:
Kate Rausch
+1 617-949-4827
krausch@wavelifesci.com
投资者联系人：
凯特·劳什
+1 617-949-4827
krausch@wavelifesci.com
Media Contact:
Alicia Suter
+1 617-949-4817
asuter@wavelifesci.com
媒体联系人：
艾丽西亚·苏特
+1 617-949-4817
asuter@wavelifesci.com
译文内容由第三方软件翻译。